Oruka Therapeutics, Inc.
No enriched coverage for $ORKA in the last 7 days.
Goncalves Joana (Chief Medical Officer) sold 7,947 shares of Oruka Therapeutics, Inc. (ORKA) at an average of $92.38 ($91.10–$95.71, $0.73M total) across 5 trades on 2026-09-15 under a Rule 10b5-1 trading plan.
Agarwal Arjun (Senior Vice President, Finance) sold 10,019 shares of Oruka Therapeutics, Inc. (ORKA) at an average of $92.43 ($91.11–$95.71, $0.93M total) across 5 trades over 2026-09-11 to 2026-09-15 under a Rule 10b5-1 trading plan.
Klein Lawrence Otto (Chief Executive Officer) sold 2,452 shares of Oruka Therapeutics, Inc. (ORKA) at $95.71 ($0.23M total) on 2026-09-15.
Recent ORKA coverage spans insider activity, financial news and corporate actions.
In the last 30 days, ORKA insiders filed 18 SEC Form 4 transactions — no purchases and 18 sales ($9.4M). The most active reporter was Goncalves Joana, Chief Medical Officer, with 5 filings. 83% of those filings were made under pre-arranged Rule 10b5-1 plans.
Minor insider sell may signal limited confidence but size is small relative to market cap.
The insider sale may signal modest downside pressure but the amount is small relative to market cap.
Insider sale may signal lack of confidence or portfolio rebalancing, potentially pressuring the stock short-term.
Executive sell could be interpreted as neutral due to pre‑planned nature.
Large insider sell may signal reduced confidence, could pressure stock short term.
AlphAI scores every news story that mentions ORKA with an AI model for sentiment and relevance, and aggregates insider trades from Oruka Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Goncalves Joana (Chief Medical Officer) sold 7,947 shares of Oruka Therapeutics, Inc. (ORKA) at an average of $92.38 ($91.10–$95.71, $0.73M total) across 5 trades on 2026-09-15 under a Rule 10b5-1 trading plan.
1 min readAgarwal Arjun (Senior Vice President, Finance) sold 10,019 shares of Oruka Therapeutics, Inc. (ORKA) at an average of $92.43 ($91.11–$95.71, $0.93M total) across 5 trades over 2026-09-11 to 2026-09-15 under a Rule 10b5-1 trading plan.
1 min readKlein Lawrence Otto (Chief Executive Officer) sold 2,452 shares of Oruka Therapeutics, Inc. (ORKA) at $95.71 ($0.23M total) on 2026-09-15.
1 min readQuoin Pharmaceuticals (QNRX) executives bought shares at $4.88 each, now at $6.51. CuriosityStream (CURI) CEO bought shares near 52-week low. FTC Solar (FTCI) director increased stake. Motorsport Games (MSGM) saw insider buying. Airbnb (ABNB) strategy officer sold $13.45M in shares. ORTHOPEDIATRICS (KIDS) saw major share sales. Oruka Therapeutics (ORKA) CEO sold $6.89M in shares. Aura Minerals (AUGO) director had net buying. Caterpillar (CAT) CEO sold $26.21M in shares.
3 min readKlein Lawrence Otto (Chief Executive Officer) sold 75,000 shares of Oruka Therapeutics, Inc. (ORKA) at an average of $91.83 ($90.79–$92.44, $6.89M total) across 3 trades on 2026-09-01 under a Rule 10b5-1 trading plan.
1 min readOruka Therapeutics, Inc. (ORKA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On July 22, 2026, Oruka Therapeutics, Inc. entered into a letter agreement with Todd Edwards pursuant to which Mr. Edwards
2 min readOruka Therapeutics Inc. (ORKA) shares have surged over 500% since September 2025, driven by positive clinical trial results for its drug candidates ORKA-001 and ORKA-002. The company announced several key developments, including trial progress, data releases, and a licensing agreement. ORKA's stock reached a 52-week high of $115.52 in August 2026. Investors are watching for upcoming data releases and trial initiations.
2 min readGoncalves Joana (Chief Medical Officer) sold 7,000 shares of Oruka Therapeutics, Inc. (ORKA) at an average of $111.84 ($109.65–$112.56, $0.78M total) across 4 trades on 2026-08-17 under a Rule 10b5-1 trading plan.
2 min readBiotech and healthcare stocks hit 52-week highs on Aug. 14, 2026 after quarterly results or acquisition news. Eton Pharmaceuticals (ETON) rose over 44% to $59.79; Q2 net product sales grew 99% YoY and profit was $11.6M. DexCom (DXCM) reached $91.96; Q2 revenue $1.31B (+13%) and 2026 revenue guidance $5.18B-$5.25B. Oruka (ORKA) touched $111.37; AtaiBeckley (ATAI) $7.28 after an Eli Lilly (LLY) deal potentially worth $3.8B. Concentra (CON) hit $35.52; Q2 revenue $606M (+10%) and profit $67M.
4 min readQuinlan Paul T (General Counsel) sold 52,000 shares of Oruka Therapeutics, Inc. (ORKA) at an average of $108.49 ($106.05–$111.14, $5.64M total) across 6 trades on 2026-08-14 under a Rule 10b5-1 trading plan.
2 min read